Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events
| Status: | Completed |
|---|---|
| Conditions: | Cardiology, Neurology |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Neurology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | July 2007 |
| End Date: | December 2011 |
Multiphase Study to Determine if Platelet Function Analysis Results Correlate With Ischemic Events and Bleeding Complications
The purpose of this study is to determine if PFA results correlate with ischemic event
outcomes as well as bleeding complications. Hypothesis is antiplatelet agents will be more
efficacious if they are administered in a dose-adjusted manner using PFA results as a guide.
outcomes as well as bleeding complications. Hypothesis is antiplatelet agents will be more
efficacious if they are administered in a dose-adjusted manner using PFA results as a guide.
Atherothrombotic disease is a leading killer of adults throughout the world. The current
mainstay for the prevention of ischemic vascular events is the use of aspirin Antiplatelet
agents are used routinely for the primary and secondary prevention of vascular events in
patients with a prior history of stroke, TIA, or at high risk for the development of
cerebrovascular disease. Numberous individual studies and meta-analyses have shown that
essentially all of the oral antiplatelet agents have limited efficacy, with relative risk
reductions in the range of 20-35%. The purpose of this study is to perform serial platelet
function assays (PFAs) on patients with cerebrovascular disease who are taking antiplatelet
agents and perform a pilot study to determine the feasibility of administering ASA as a dose
adjusted medication using PFA. The long term goal of this study is to determine whether
antiplatelet therapy will be more efficacious and/or safer if it is administered in a
dose-adjusted manner.
mainstay for the prevention of ischemic vascular events is the use of aspirin Antiplatelet
agents are used routinely for the primary and secondary prevention of vascular events in
patients with a prior history of stroke, TIA, or at high risk for the development of
cerebrovascular disease. Numberous individual studies and meta-analyses have shown that
essentially all of the oral antiplatelet agents have limited efficacy, with relative risk
reductions in the range of 20-35%. The purpose of this study is to perform serial platelet
function assays (PFAs) on patients with cerebrovascular disease who are taking antiplatelet
agents and perform a pilot study to determine the feasibility of administering ASA as a dose
adjusted medication using PFA. The long term goal of this study is to determine whether
antiplatelet therapy will be more efficacious and/or safer if it is administered in a
dose-adjusted manner.
Inclusion Criteria:
- Patient must be taking Aspirin or Plavix
- Patient must have had a stroke, TIA or cerebrovascular disease
Exclusion Criteria:
We found this trial at
1
site
Click here to add this to my saved trials
